Overview

Safety and Efficacy Comparator Trial of a New Drug Against Genital Herpes

Status:
Terminated
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
The aim of the study is to evaluate the safety and efficacy of "AIC316 (pritelivir)" 100 mg once daily compared to valacyclovir 500 mg once daily for the prevention of HSV-2 genital shedding.
Phase:
Phase 2
Details
Lead Sponsor:
AiCuris Anti-infective Cures GmbH
Collaborator:
Medpace, Inc.
Treatments:
Acyclovir
Pritelivir
Valacyclovir